Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application - Takeaways - MDSpire

Emerging Insights on Circulating Tumor DNA in Sarcoma: Navigating Clinical Challenges and Potential Applications

  • By

  • Kristin E. Goodsell

  • Jason A. Carter

  • Hannah R. Abrams

  • Harveshp Mogal

  • Elizabeth T. Loggers

  • Jeremy Sharib

  • July 12, 2026

Share

  • 1

    Sarcomas comprise over 100 histological and molecular subtypes, presenting challenges for diagnosis and treatment.

  • 2

    Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and detecting disease recurrence.

  • 3

    Current studies on ctDNA in sarcoma are limited, highlighting the need for further research in this area.

  • 4

    ctDNA levels correlate with tumor dynamics, offering potential applications in early diagnosis and disease monitoring.

  • 5

    The review discusses the status of ctDNA in sarcomas and compares it to its established use in other solid tumors.

Original Source(s)

Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application

  • by Kristin E. Goodsell, Jason A. Carter, Hannah R. Abrams, Harveshp Mogal, Elizabeth T. Loggers, Jeremy Sharib

  • July 12, 2026

Related Content

Multitask learning for early treatment response and survival prediction in lung cancer radiotherapy using sequential CBCT imaging

Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report

Pre-transplant measurable residual disease by flow cytometry is an independent prognostic factor in pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation